Kalaris Therapeutics, Inc. (KLRS)
2.26
-0.10
(-4.24%)
USD |
NASDAQ |
Oct 12, 16:00
2.23
-0.03
(-1.33%)
Pre-Market: 20:00
Kalaris Therapeutics EPS Diluted (Quarterly) : -0.4839 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.4839 |
| March 31, 2026 | -0.4576 |
| December 31, 2025 | -0.4366 |
| September 30, 2025 | -0.636 |
| June 30, 2025 | -0.6069 |
| March 31, 2025 | -2.516 |
| December 31, 2024 | -16.24 |
| September 30, 2024 | -28.16 |
| June 30, 2024 | -4.262 |
| March 31, 2024 | -59.70 |
| December 31, 2023 | -12.05 |
| September 30, 2023 | -8.940 |
| June 30, 2023 | -11.00 |
| March 31, 2023 | -10.15 |
| December 31, 2022 | -9.422 |
| Date | Value |
|---|---|
| September 30, 2022 | -11.39 |
| June 30, 2022 | -15.93 |
| March 31, 2022 | -15.76 |
| December 31, 2021 | -20.96 |
| September 30, 2021 | -16.62 |
| June 30, 2021 | -13.87 |
| March 31, 2021 | -11.44 |
| December 31, 2020 | -9.358 |
| September 30, 2020 | -13.42 |
| June 30, 2020 | -4.109 |
| March 31, 2020 | -3.299 |
| December 31, 2019 | -3.089 |
| September 30, 2019 | -2.568 |
| June 30, 2019 | -1.873 |
| March 31, 2019 | -0.8917 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Replimune Group, Inc. | -0.7202 |
| Arrowhead Pharmaceuticals, Inc. | -1.355 |
| Oncolytics Biotech, Inc. | -0.0788 |
| Sangamo Therapeutics, Inc. | -0.0796 |
| Sarepta Therapeutics, Inc. | -0.0464 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -11.52M |
| Total Expenses (Quarterly) | 11.52M |
| Enterprise Value | -38.34M |
| Earnings Yield | -89.12% |
| Normalized Earnings Yield | -89.12 |